4:56 PM ET
8-K
Investor Presentation
Acrivon Therapeutics Investor Presentation
Acrivon Therapeutics hosted a corporate R&D event and webcast featuring Key Opinion Leaders to introduce its new immunology and inflammation (I&I) programs, ACR-525 and a PKCθ inhibitor. The company filed a formal investor presentation deck detailing the preclinical programs and development plans for Eosinophilic esophagitis (EoE) identified via its AP3 platform.